STOCK TITAN

Artelo Biosciences, Inc. - ARTL STOCK NEWS

Welcome to our dedicated page for Artelo Biosciences news (Ticker: ARTL), a resource for investors and traders seeking the latest updates and insights on Artelo Biosciences stock.

Artelo Biosciences, Inc. (NASDAQ: ARTL) is a clinical-stage biopharmaceutical company headquartered in San Diego, California, with an additional office in Dublin, Ireland. The company is dedicated to the development and commercialization of proprietary therapeutics that modulate lipid signaling pathways, including the endocannabinoid system. Artelo leverages past research and cutting-edge science to accelerate the development of a diverse portfolio of novel therapeutics with the potential to dramatically improve patient care in major markets.

Core to Artelo's mission is their focus on discovering, licensing, developing, and commercializing treatments that control endocannabinoid systems. This includes cannabinoid-based therapies, both derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds. The company's flagship program is a patent-protected cannabinoid drug combination treatment aimed at rare and orphan diseases.

One of their notable projects, ART12.11, has demonstrated improved bioavailability of CBD in both fed and fasted states compared to CBD alone. This proprietary cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP) offers biopharmaceutic advantages over standard CBD compositions, showing better pharmacokinetics and improved efficacy in preclinical studies. The US-issued composition of matter patent for ART12.11 is enforceable until December 10, 2038.

Another significant program is ART26.12, a Fatty Acid Binding Protein 5 (FABP5) inhibitor being developed as a non-opioid, non-steroidal analgesic for chemotherapy-induced peripheral neuropathy (CIPN) and potentially other neuropathic pains. ART26.12 has shown promising results in preclinical studies, reducing pain in models of diabetic neuropathy and chemotherapy-induced peripheral neuropathy.

Artelo is also advancing ART27.13, a G-Protein Coupled Receptor (GPCR) agonist targeting CB1 and CB2 receptors. This program is currently in the Cancer Appetite Recovery Study (CAReS) Phase 2a trial, aimed at improving body weight, appetite, muscle degeneration, and quality of life in cancer patients. The company has reported positive progress in clinical trials and aims to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, pain, neuropathy, and inflammation.

Led by experienced biopharmaceutical executives and backed by collaborations with highly respected researchers and technology experts, Artelo applies rigorous scientific, regulatory, and commercial discipline to develop high-impact therapies. The company maintains a strong presence in global biopharma innovation hubs, ensuring close access to world-class research expertise.

Rhea-AI Summary

Artelo Biosciences (NASDAQ: ARTL) will present at the H.C. Wainwright Life Sciences Conference, scheduled for March 9-10, 2021. Gregory Gorgas, CEO, will provide insights on the company's development of therapeutics targeting the endocannabinoid system. The presentation will be available on-demand from March 9 at 7:00 AM Eastern Time on the conference platform. Additionally, Artelo's management will hold one-on-one meetings with qualified investors during the event, highlighting its focus on addressing unmet needs in various diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.1%
Tags
conferences
-
Rhea-AI Summary

Artelo Biosciences (NASDAQ: ARTL) announced promising findings from research highlighting the co-administration of cannabidiol (CBD) and tetramethylpyrazine (TMP) in cancer cell models. Conducted by experts from the University of Nottingham, the study suggests enhanced anti-cancer effects through synergistic interactions between the two compounds, although a slight reduction in CBD's anti-migration effect was noted. Artelo aims for further in vivo research and has secured a composition of matter patent, opening opportunities for clinical approval and market exclusivity for its CBD:TMP cocrystal program.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.18%
Tags
-
Rhea-AI Summary

Artelo Biosciences (NASDAQ: ARTL) has appointed Andrew Yates, Ph.D., as Senior VP and Chief Scientific Officer, effective immediately. Yates brings extensive experience from AstraZeneca, where he played key roles in drug development and strategy. He will lead the R&D efforts and engage with the Scientific Advisory Board, enhancing Artelo's clinical development initiatives, particularly for ART27.13, aimed at addressing cancer-related anorexia. His appointment is expected to strengthen the company's capabilities in developing therapies for various conditions, including PTSD and pain.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.88%
Tags
management
Rhea-AI Summary

Artelo Biosciences (NASDAQ: ARTL) announced the exercise of warrants from its October 2020 financing, resulting in net proceeds of approximately $3 million. This strengthens the company's balance sheet, leading to a pro-forma cash balance of $10.4 million as of November 30, 2020. The capital raised will be utilized to advance the company’s product development aimed at addressing unmet needs in various diseases, including cancer and pain.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.47%
Tags
none
-
Rhea-AI Summary

Artelo Biosciences (NASDAQ: ARTL) will present at the LSX World Congress virtually from February 1-5, 2021. The presentation will be available on-demand to registered attendees until February 28, 2021. This event brings together key executives in healthcare and life sciences, providing a platform for investment and strategic discussions. Artelo focuses on therapeutics targeting the endocannabinoid system, addressing conditions like cancer and pain. More details can be found at their website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.56%
Tags
conferences
-
Rhea-AI Summary

Artelo Biosciences (ARTL) announced the receipt of Clinical Trials Authorization for its Cancer Appetite Recovery Study (CAReS) of ART27.13 in the UK. This Phase I/II trial targets cancer patients suffering from anorexia, addressing a significant unmet medical need. The company also secured a Mitacs Accelerate grant to further develop its ART26.12 program, exploring its potential in treating anxiety disorders. Financially, ARTL reported a net loss of $1.43 million for Q1 FY2021, with operating expenses slightly rising to $1.44 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1%
Tags
Rhea-AI Summary

Artelo Biosciences (NASDAQ: ARTL) announced its participation in the H.C. Wainwright BioConnect 2021 Conference, scheduled for January 11-14, 2021. The presentation will be available on-demand starting January 11 at 6:00 a.m. EDT and accessible for 90 days. Artelo is focused on developing therapeutics that modulate the endocannabinoid system to address unmet medical needs in conditions such as cancer, PTSD, and pain. The company is based in San Diego and is advancing a portfolio of product candidates aimed at various diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.99%
Tags
conferences
-
Rhea-AI Summary

Artelo Biosciences (NASDAQ: ARTL) has filed a composition of matter patent application with the UK Patent Office for a new solid dosage formulation related to its lead clinical program, ART27.13. This formulation aims to treat cancer patients suffering from anorexia. The company has received Clinical Trial Authorization for its Cancer Appetite Recovery Study (CAReS) and plans to begin enrollment by year-end 2020. If allowed, the patent application is expected to secure exclusivity for ART27.13 through 2041.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.72%
Tags
none
-
Rhea-AI Summary

Artelo Biosciences (NASDAQ: ARTL) announced its participation in the 13th Annual LD Micro Main Event investor conference on December 15 at 9:40 a.m. PST. Gregory D. Gorgas, President and CEO, will present to a live virtual audience. The conference format includes a 10-minute presentation followed by a Q&A session. The Main Event takes place on December 14-15 on the Sequire Virtual Events platform. Artelo is focused on developing therapeutics targeting the endocannabinoid system, addressing unmet medical needs in various conditions such as cancer and pain.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.26%
Tags
conferences
Rhea-AI Summary

Artelo Biosciences (NASDAQ: ARTL) announced the appointment of Gregory R. Reyes, M.D., Ph.D., to its Board of Directors, effective November 30, 2020. Dr. Reyes brings over 35 years of experience in biotech and pharmaceuticals, having advanced over 50 drug candidates in his career. He previously held significant positions at Celgene, Biogen Idec, Pfizer, and Schering-Plough, contributing to the development of successful therapeutics like Merck’s Victrelis. Artelo aims to leverage Dr. Reyes' expertise to enhance its clinical development and product pipeline.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.67%
Tags
management

FAQ

What is the current stock price of Artelo Biosciences (ARTL)?

The current stock price of Artelo Biosciences (ARTL) is $0.9476 as of December 20, 2024.

What is the market cap of Artelo Biosciences (ARTL)?

The market cap of Artelo Biosciences (ARTL) is approximately 3.0M.

What does Artelo Biosciences do?

Artelo Biosciences is a clinical-stage biopharmaceutical company focused on developing and commercializing proprietary therapeutics that modulate lipid signaling pathways, including the endocannabinoid system.

Where is Artelo Biosciences headquartered?

Artelo Biosciences is headquartered in San Diego, California, with an additional office in Dublin, Ireland.

What are the main therapeutic areas Artelo Biosciences focuses on?

Artelo Biosciences focuses on developing treatments for anorexia, cancer, anxiety, pain, neuropathy, and inflammation.

What is ART12.11?

ART12.11 is Artelo’s proprietary cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP), which has shown improved bioavailability and efficacy compared to standard CBD compositions.

What is ART26.12?

ART26.12 is a Fatty Acid Binding Protein 5 (FABP5) inhibitor being developed by Artelo as a non-opioid, non-steroidal analgesic for treating chemotherapy-induced peripheral neuropathy (CIPN) and other neuropathic pains.

What is ART27.13?

ART27.13 is a G-Protein Coupled Receptor (GPCR) agonist targeting CB1 and CB2 receptors, currently in the Cancer Appetite Recovery Study (CAReS) Phase 2a trial to improve body weight, appetite, and muscle degeneration in cancer patients.

What recent achievement has ART12.11 demonstrated?

ART12.11 has demonstrated improved bioavailability of CBD in both fed and fasted states compared to CBD alone, providing better pharmacokinetics and efficacy.

What progress has been made in the ART26.12 program?

In preclinical studies, ART26.12 has shown efficacy in reducing pain in models of chemotherapy-induced peripheral neuropathy (CIPN) and diabetic neuropathy.

Who leads Artelo Biosciences?

Artelo Biosciences is led by experienced biopharmaceutical executives working in collaboration with highly respected researchers and technology experts.

Where can I find more information about Artelo Biosciences?

More information about Artelo Biosciences is available on their website, www.artelobio.com, and on Twitter @ArteloBio.

Artelo Biosciences, Inc.

Nasdaq:ARTL

ARTL Rankings

ARTL Stock Data

3.00M
3.20M
0.83%
0.72%
0.62%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SOLANA BEACH